CYP17-IN-1
CAS No. 2093317-51-0
CYP17-IN-1( —— )
Catalog No. M26134 CAS No. 2093317-51-0
CYP17-IN-1 is an effective oral CYP17 inhibitor that can inhibit CYP17 in rats and humans with IC50 of 15.8 and 20.1 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 264 | Get Quote |
|
| 5MG | 403 | Get Quote |
|
| 10MG | 592 | Get Quote |
|
| 25MG | 888 | Get Quote |
|
| 50MG | 1242 | Get Quote |
|
| 100MG | 1701 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCYP17-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCYP17-IN-1 is an effective oral CYP17 inhibitor that can inhibit CYP17 in rats and humans with IC50 of 15.8 and 20.1 nM.
-
DescriptionCYP17-IN-1 is an effective oral CYP17 inhibitor that can inhibit CYP17 in rats and humans with IC50 of 15.8 and 20.1 nM.(In Vitro):The IC50 value of CYP17-IN-1 for CYP3A4 is 8.5 μM.(In Vivo):CYP17-IN-1 dose-dependently reduced plasma testosterone levels in Sprague-Dawley rats.
-
In VitroCYP17-IN-1 (compound 9c) exhibits an IC50 value of 8.5 μM against CYP3A4.
-
In VivoCYP17-IN-1 (compound 9c) reduces plasma testosterone level in a dose-dependent manner in Sprague-Dawley rats.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetP450
-
Recptorcarbonic anhydrase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2093317-51-0
-
Formula Weight312.41
-
Molecular FormulaC18H17FN2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1ccncc1CN1CCc2c(C1)sc1ccc(F)cc21
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Prete SD, et, al. Escherichia coli γ-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1545-1554.
molnova catalog
related products
-
Guan-fu base A
Guanfu base A is a potent noncompetitive CYP2D6 inhibitor (Ki: 1.20 μM in HLMs; Ki: 0.37 μM for rCYP2D6). It also inhibits HERG channel current.
-
Ambroxol
Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.
-
Verapamil
Verapamil is a calcium channel blocker and an orally active and effective inhibitor of P-gp.
Cart
sales@molnova.com